Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Habuchi, T.
Right arrow Articles by Kato, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Habuchi, T.
Right arrow Articles by Kato, T.
[Cancer Research 60, 5710-5713, October 15, 2000]
© 2000 American Association for Cancer Research

Regular Articles

Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect1

Tomonori Habuchi2, Zhang Liqing2, Takehiro Suzuki, Ryusei Sasaki, Norihiko Tsuchiya, Hiroshi Tachiki, Naotake Shimoda, Shigeru Satoh, Kazunari Sato, Yoshiyuki Kakehi, Toshiyuki Kamoto, Osamu Ogawa and Tetsuro Kato3

Department of Urology [T. H., Z. L., T. S., R. S., N. T., H. T., N. S., S. S., K. S., T. Kat.], Akita University School of Medicine, Akita 010-8543, Japan, and Department of Urology [Y. K., T. Kam., O. O.], Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan

The CYP17 gene (CYP17) codes for the cytochrome P450c17{alpha} enzyme, which mediates two key steps in the sex steroid synthesis. There is a polymorphism (a T-to-C substitution) in the 5'-untranslated region, which may influence the transcription level of CYP17 mRNA. There is a continuing controversy as to whether the variant allele is associated with a subset of breast cancer or polycystic ovary syndrome. In prostate cancer research, there are contradictory data concerning the CYP17 risk allele. We explored the association between CYP17 polymorphism and a risk of prostate cancer or benign prostatic hyperplasia (BPH) in a Japanese population. This study included 252 prostate cancer patients, 202 BPH patients, and 131 male controls. A 451-bp fragment encompassing the polymorphic site was amplified by PCR, treated with restriction enzyme MspA1, and electrophoresed on an agarose gel. The MspA1-undigested allele with the published sequence and the MspA1-digested variant allele were designated as A1 and A2, respectively. There was a significant difference (P < 0.05) in the genotypes between prostate cancer patients and male controls, and between BPH patients and male controls. Men with the A1/A1 CYP17 genotype had an increased risk of prostate cancer [odds ratio (OR), 2.57; 95% confidence interval (CI) = 1.39–4.78] and BPH (OR, 2.44; 95% CI = 1.26–4.72) compared with those with the A2/A2 genotype. Men with the A1/A2 genotype had an intermediate increased risk of prostate cancer (OR, 1.45; 95% CI = 0.84–2.54) and BPH (OR, 1.60; 95% CI = 0.89–2.87) compared with those with the A2/A2 genotype. The trend of an increasing risk of prostate cancer and BPH with an increasing number of the A1 allele was statistically significant (prostate cancer versus male control, P = 0.003; OR, 1.57; 95% CI = 1.16–2.12; BPH versus male control, P = 0.008; OR, 1.55; 95% CI = 1.12–2.13). There was no significant association between the CYP17 genotype and the tumor status (grade and stage) of prostate cancer. Our results suggest that the A1 allele of the CYP17 polymorphism is associated with an increased risk of prostate cancer and BPH, with a gene dosage effect. However, the CYP17 genotype does not seem to influence the disease status in prostate cancer.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
R. C. SOBTI, L. GUPTA, H. THAKUR, A. SETH, S. K. SINGH, and P. KAUR
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients
Anticancer Res, May 1, 2009; 29(5): 1659 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. W. Bell, B. W. Brannigan, K. Matsuo, D. M. Finkelstein, R. Sordella, J. Settleman, T. Mitsudomi, and D. A. Haber
Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms
Clin. Cancer Res., July 1, 2008; 14(13): 4079 - 4084.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Tsuchiya, L. Wang, H. Suzuki, T. Segawa, H. Fukuda, S. Narita, M. Shimbo, T. Kamoto, K. Mitsumori, T. Ichikawa, et al.
Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer
J. Clin. Oncol., May 1, 2006; 24(13): 1982 - 1989.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Tanaka, M. Sasaki, H. Shiina, T. Tokizane, M. Deguchi, H. Hirata, Y. Hinoda, N. Okayama, Y. Suehiro, S. Urakami, et al.
Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 238 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Douglas, K. A. Zuhlke, J. Beebe-Dimmer, A. M. Levin, S. B. Gruber, D. P. Wood, and K. A. Cooney
Identifying Susceptibility Genes for Prostate Cancer--A Family-Based Association Study of Polymorphisms in CYP17, CYP19, CYP11A1, and LH-{beta}
Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 2035 - 2039.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Kamoto, Y. Isogawa, Y. Shimizu, S. Minamiguchi, H. Kinoshita, Y. Kakehi, K. Mitsumori, S. Yamamoto, T. Habuchi, T. Kato, et al.
Association of a Genetic Polymorphism of the E-cadherin Gene with Prostate Cancer in a Japanese Population
Jpn. J. Clin. Oncol., March 1, 2005; 35(3): 158 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little
CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review
Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Li, T. Habuchi, N. Tsuchiya, K. Mitsumori, L. Wang, C. Ohyama, K. Sato, T. Kamoto, O. Ogawa, and T. Kato
Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10
Carcinogenesis, February 1, 2004; 25(2): 237 - 240.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wang, T. Habuchi, N. Tsuchiya, K. Mitsumori, C. Ohyama, K. Sato, H. Kinoshita, T. Kamoto, A. Nakamura, O. Ogawa, et al.
Insulin-like Growth Factor-binding Protein-3 Gene -202 A/C Polymorphism Is Correlated with Advanced Disease Status in Prostate Cancer
Cancer Res., August 1, 2003; 63(15): 4407 - 4411.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. G. Nelson, A. M. De Marzo, and W. B. Isaacs
Prostate Cancer
N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis
Association of the CYP17 Gene Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis
Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 120 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck
Inherited Genotype and Prostate Cancer Outcomes
Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Simard, M. Dumont, P. Soucy, and F. Labrie
Perspective: Prostate Cancer Susceptibility Genes
Endocrinology, June 1, 2002; 143(6): 2029 - 2040.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. L. Stanford, E. A. Noonan, L. Iwasaki, S. Kolb, R. B. Chadwick, Z. Feng, and E. A. Ostrander
A Polymorphism in the CYP17 Gene and Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 243 - 247.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen
Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men
J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. W. Hsing, C. Chen, A. P. Chokkalingam, Y.-T. Gao, D. A. Dightman, H. T. Nguyen, J. Deng, J. Cheng, I. A. Sesterhenn, F. K. Mostofi, et al.
Polymorphic Markers in the SRD5A2 Gene and Prostate Cancer Risk: A Population-based Case-control Study
Cancer Epidemiol. Biomarkers Prev., October 1, 2001; 10(10): 1077 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. A. Kittles, R. K. Panguluri, W. Chen, A. Massac, C. Ahaghotu, A. Jackson, F. Ukoli, L. Adams-Campbell, W. Isaacs, and G. M. Dunston
CYP17 Promoter Variant Associated with Prostate Cancer Aggressiveness in African Americans
Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 943 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. A. Haiman, M. J. Stampfer, E. Giovannucci, J. Ma, N. E. Decalo, P. W. Kantoff, and D. J. Hunter
The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 743 - 748.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.